Eli Lilly (LLY) Capital Expenditures Growth (5y) (2014 - 2026)

Eli Lilly (LLY) Capital Expenditures Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 50.60%
Dec 31, 2025 41.14%
Sep 30, 2025 39.65%
Jun 30, 2025 43.19%
Mar 31, 2025 42.35%
Dec 31, 2024 35.59%
Sep 30, 2024 38.67%
Jun 30, 2024 38.50%
Mar 31, 2024 37.09%
Dec 31, 2023 22.12%
Sep 30, 2023 29.17%
Jun 30, 2023 18.95%
Mar 31, 2023 23.10%
Dec 31, 2022 2.46%
Sep 30, 2022 20.52%
Jun 30, 2022 10.86%
Mar 31, 2022 16.67%
Dec 31, 2021 -6.59%
Sep 30, 2021 8.16%
Jun 30, 2021 9.21%